At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 115 enrolled
Drug / intervention
Brequinar +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The CRISIS2 Study: A Phase 2, Randomized, Double Blind, Placebo-controlled, Multi-center Study Assessing the Safety and Anti-coronavirus Response of Suppression of Host Nucleotide Synthesis in Out-patient Adults With SARS-CoV-2
In Brief
A Phase 2 clinical trial evaluating Brequinar and Placebo for COVID-19 Infection. Completed, enrolled 115 participants across 14 sites.
Detailed Summary
This study will assess the efficacy and safety of DHODHi (brequinar) as an antiviral via 5 days of treatment of participants with positive COVID-19 and at least one symptom of COVI019 in an out-patient setting. The study is multi-center, randomized, and placebo-controlled.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19 Infection
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedOct 2020
Enrollment StartNov 2020
Primary CompletionApr 2021
TodayJul 2026
First PostedOct 5, 2020
Enrollment StartNov 19, 2020
Primary CompletionApr 28, 2021
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 5.7 years ago
Interventions
Brequinardrug
Dihydroorotate dehydrogenase inhibitor (DHODHi)
Placebodrug
Placebo capsules